Skip to main content
Clinical Trials/NCT01212601
NCT01212601
Completed
N/A

A Multicenter, Observational, Non-interventional Registry Designed to Collect Clinical Data in Chinese Patients Who Have Received CUBICIN® Treatment Under Condition of Actual Usage in Clinical Practice

AstraZeneca1 site in 1 country203 target enrollmentJanuary 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
S. Aureus Bloodstream Infection
Sponsor
AstraZeneca
Enrollment
203
Locations
1
Primary Endpoint
AEs of CUBICIN therapy
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

Detailed Description

MC MD

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
November 2012
Last Updated
13 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient has received CUBICIN treatment, decided by treating physician
  • A patient who is considered as ethnic Chinese
  • Provision of subject informed consent

Exclusion Criteria

  • A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.

Outcomes

Primary Outcomes

AEs of CUBICIN therapy

Time Frame: 2 weeks

clinical response of CUBICIN therapy at each available time point

Time Frame: 2 weeks

Secondary Outcomes

  • CPK level monitoring and results(2 weeks)
  • treatment duration(2 weeks)
  • Time to clinical response(2 weeks)

Study Sites (1)

Loading locations...

Similar Trials